

Stockholm, 5 June 2012

Sobi to refinance existing credit facility

Sobi has decided to refinance its existing credit facility either by issuing a SEK denominated bond up to SEK 500 M or by entering into a new revolving credit facility with SEB and Nordea.

The purpose of the refinancing is to improve the financial flexibility and to extend the maturity profile. The refinancing will replace existing bank debt and will not increase Sobi's total debt.

Sobi has appointed Nordea as Joint Bookrunner and Co-ordinator together with SEB as Joint Bookrunner to investigate a bond issue. The lead banks Nordea and SEB have committed to provide a credit facility in a corresponding amount in the event that Sobi does not proceed with the bond issue.

For further information, please contact:

Lars Sandström, CFO

Tel.: +46 8 697 26 33

Swedish Orphan Biovitrum (Sobi)

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 5 June 2012 at 16.50 CET.